Kepler Capital Sticks to Their Buy Rating for Smith & Nephew (SN)

In a report released on December 8, Christophe dombu from Kepler Capital maintained a Buy rating on Smith & Nephew, with a price target of p1,462.00. The company’s shares closed yesterday at p1,265.00.

Claim 50% Off TipRanks Premium and Invest with Confidence

• Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential

dombu covers the Healthcare sector, focusing on stocks such as Hyloris Pharmaceuticals SA, Nyxoah, and Galapagos. According to TipRanks, dombu has an average return of -4.3% and a 50.00% success rate on recommended stocks.

Currently, the analyst consensus on Smith & Nephew is a Moderate Buy with an average price target of p1,501.25, which is a 18.68% upside from current levels. In a report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a p1,600.00 price target.

Based on Smith & Nephew’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of p2.99 billion and a net profit of p295.65 million. In comparison, last year the company earned a revenue of p2.83 billion and had a net profit of p214 million

Based on the recent corporate insider activity of 74 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SN in relation to earlier this year.